Syndax Pharmaceuticals, Inc. Deferred Tax Assets, Tax Deferred Expense
Syndax Pharmaceuticals, Inc. (SNDX) had Deferred Tax Assets, Tax Deferred Expense of $53.70 million as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpense · last filed 2024-02-27
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense $53.70M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense $22.20M.
| Period end | Deferred Tax Assets, Tax Deferred Expense |
|---|---|
| 2023-12-31 | $53.70M 10-K · filed 2024-02-27 |
| 2022-12-31 | $22.20M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |